Composition of 2,4,6- trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide

Abstract

The present invention relates to discloses a pharmaceutical composition of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide and a pharmaceutically acceptable carrier.

1 . A pharmaceutical composition comprising an amount of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent or carrier, wherein for oral or rectal administration said composition comprises 50-400 mg per dose of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide or a pharmaceutically acceptable salt thereof and for buccal, sublingual, nasal/intranasal, transdermal, subcutaneous, injectable, intravenous or intramuscular administration said composition comprises up to 200 mg per dose of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide or a pharmaceutically acceptable salt thereof, further wherein said composition is administered one, two, or three times daily. 
     
     
         2 . The pharmaceutical composition according to  claim 1 , wherein said composition is for oral or rectal administration and the amount of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide or pharmaceutically acceptable salt thereof is from 50 mg to 400 mg per dose. 
     
     
         3 . The pharmaceutical composition according to  claim 2 , wherein the amount of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide is 50 mg per dose. 
     
     
         4 . The pharmaceutical composition according to  claim 2 , wherein the amount of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide is 100 mg per dose. 
     
     
         5 . The pharmaceutical composition according to  claim 2 , wherein the amount of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide is 200 mg per dose. 
     
     
         6 . The pharmaceutical composition according to  claim 2 , wherein the amount of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide is 400 mg per dose. 
     
     
         7 . The pharmaceutical composition according to  claim 1 , wherein said composition is for buccal, sublingual, nasal/intranasal, transdermal, subcutaneous, injectable, intravenous, or intramuscular administration and the amount of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide or pharmaceutically acceptable salt thereof is up to 200 mg per dose. 
     
     
         8 . The pharmaceutical composition according to  claim 7 , wherein the amount of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide or a pharmaceutically acceptable salt thereof is 20 mg to 200 mg per dose. 
     
     
         9 . The pharmaceutical composition according to  claim 8 , wherein the amount of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide or a pharmaceutically acceptable salt thereof is from 20 to 60 mg per dose. 
     
     
         10 . The pharmaceutical composition according to  claim 9 , wherein the amount of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide or a pharmaceutically acceptable salt thereof is from 20 to 30 mg per dose. 
     
     
         11 . The pharmaceutical composition according to  claim 7 , wherein the administration is intravenous. 
     
     
         12 . The pharmaceutical composition according to  claim 11 , wherein the administration is over a period of about 20 minutes. 
     
     
         13 . The pharmaceutical composition according to  claim 1 , wherein the composition comprises the hemi-succinate salt of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide. 
     
     
         14 . The pharmaceutical composition according to  claim 1 , wherein the dose of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide or a pharmaceutically acceptable salt thereof is administered one time daily. 
     
     
         15 . The pharmaceutical composition according to  claim 1 , wherein the dose of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide or a pharmaceutically acceptable salt thereof is administered two times daily. 
     
     
         16 . The pharmaceutical composition according to  claim 1 , wherein the dose of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide or a pharmaceutically acceptable salt thereof is administered three times daily. 
     
     
         17 . A method for the treatment or prevention of migraine in a mammal in need thereof comprising administering to the mammal an effective amount of a pharmaceutical composition, wherein said composition comprises an amount of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent or carrier, further wherein for oral or rectal administration said composition comprises 50-400 mg per dose of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide or a pharmaceutically acceptable salt thereof and for buccal, sublingual, nasal/intranasal, transdermal, subcutaneous, injectable, intravenous or intramuscular administration said composition comprises up to 200 mg per dose of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide or a pharmaceutically acceptable salt thereof, and wherein said composition is administered one, two, or three times daily. 
     
     
         18 . The method of  claim 17 , wherein the mammal is a human. 
     
     
         19 . The method of  claim 17 , comprising administering an amount of 20 mg of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide hemisuccinate salt by intravenous administration over 20 minutes one time daily. 
     
     
         20 . The method of  claim 19 , wherein said amount is administered for the prevention of migraine.